Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Medivir's CEO to BioStock: "The IND approval is a very important milestone"

Medivir

Medivir has secured FDA approval to proceed with a phase IIb trial evaluating fostrox in combination with Lenvima for second-line treatment of advanced liver cancer. The trial will evaluate the combination's effect compared to Lenvima alone, building on encouraging phase Ib/IIa results, aiming to bevome the first, approved treatment option in second-line liver cancer. We reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/12/medivirs-ceo-the-ind-approval-is-a-very-important-milestone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.